Publications.

*******************************************
FLAGSHIP PUBLICATIONS
*******************************************

Bejan-Angoulvant T, Ternant D, Daoued F, Medina F, Bernard L, Paintaud G, Mulleman D.
Brief report: Relationship between infliximab serum concentrations and risk of infections in patients treated for inflammatory arthritis.
Ann Rheum Dis. 2017, 69 : 108-113.

Cartron G, Watier H.
Obinutuzumab: what is there to learn from clinical trials?
Blood 2017, 130 : 581-589

Chaigne B, Watier H.
Theranostic of biopharmaceuticals.
Pharmacology & Therapeutics 2017, 175 : 67-74

Gruel Y
Analysis of big data for heparin-induced thrombocytopenia: valuable information but also some doubts.
Lancet Haematol. 2018 May;5(5):e188-e189.

Juen L, Brachet-Botineau M, Parmenon C, Bourgeais J, Hérault O, Gouilleux F, Viaud-Massuard MC, Prié G.
New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias.
J Med Chem. 2017,60 : 6119-6136

Kizlik-Masson C, Vayne C, McKenzie SE, Poupon A, Zhou Y, Champier G, Pouplard C, Gruel Y, Rollin J.
5B9, a monoclonal anti-platelet factor 4 /heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.
J Thromb Haemost. 2017 Aug 3. doi: 10.1111/jth.13786. [Epub ahead of print]

Mulleman D, Balsa A.
Adalimumab concentration-based tapering strategy: as good as the recommended dosage.
Ann Rheum Dis. 2018 Jan 6. pii: annrheumdis-2017-212376. doi: 10.1136/annrheumdis-2017-212376. [Epub ahead of print]

Oyallon B, Brachet-Botineau M, Logé C, Bonnet P, Souab M, Robert T, Ruchaud S, Bach S, Berthelot P, Gouilleux F, Viaud-Massuard MC, Denevault-Sabourin C.
Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.
Eur J Med Chem. 2018, 154 : 101-109.

Ternant D, Azzopardi N, Raoul W, Bejan-Angoulvant T, Paintaud G.
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.
Clin Pharmacokinet. 2018 May 26. doi: 10.1007/s40262-018-0680-3. [Epub ahead of print]
 
*************************************
SELECTION OF PUBLICATIONS ISSUED IN 2018
*************************************
Aubrey N, Allard-Vannier E, Martin C, Bryden F, Letast S, Colas C, Lakhrif Z, Collinet N, Dimier-Poisson I, Chourpa I, Viaud-Massuard MC, Joubert N.
Site-Specific Conjugation of Auristatins onto Engineered scFv using Second Generation Maleimide to Target HER2-positive Breast Cancer in vitro.
Bioconjug Chem. 2018 Oct 23. doi: 10.1021/acs.bioconjchem.8b00668. [Epub ahead of print]

Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P.
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.
Ann Oncol. 2018 Feb 9. doi: 10.1093/annonc/mdy061. [Epub ahead of print]

Bachet JB, Lucidarme O, Levache CB, Barbier E, Raoul JL, Lecomte T, Desauw C, Brocard F, Pernot S, Breysacher G, Lagasse JP, Di Fiore F, Etienne PL, Dupuis OJM, Aleba A, Lepage C, Taieb J; for FFCD 1102 investigators.
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Eur J Cancer. 2018 Oct 18;104:108-116. doi: 10.1016/j.ejca.2018.09.006. [Epub ahead of print]

Bonneau C, Paintaud G, Trédan O, Dubot C, Desvignes C, Dieras V, Taillibert S, Tresca P, Turbiez I, Li J, Passot C, Mefti F, Mouret-Fourme E, Le Rhun E, Gutierrez M.
Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
Eur. J. Cancer. 2018, 95 : 75-84

Bouché O, Cesne AL, Rios M, Chaigneau L, Italiano A, Duffaud F, Lecomte T, Arsène D, Manfredi S, Aparicio T, Remy S, Isambert N, Collard O, Priou F, Bertucci F, Sambuc R, Bisot-Locard S, Bourges O, Chabaud S, Blay JY.
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.
PLoS One. 2018 Sep 18;13(9):e0204117.

Bourquard T, Musnier A, Puard V, Tahir S, Ayoub MA, Jullian Y, Boulo T, Gallay N, Watier H, Bruneau G, Reiter E, Crépieux P, Poupon A.
MAbTope: A Method for Improved Epitope Mapping.
J Immunol. 2018 Nov 15;201(10):3096-3105. doi: 10.4049/jimmunol.1701722. Epub 2018 Oct 15.

Bryden F, Martin C, Letast S, Lles E, Viéitez-Villemin I, Rousseau A, Colas C, Brachet-Botineau M, Allard-Vannier E, Larbouret C, Viaud-Massuard MC, Joubert N.
Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
Org Biomol Chem. 2018 Mar, 16 : 1882-1889.

Castaneda DC, Dhommée C, Baranek T, Dalloneau E, Lajoie L, Valayer A, Arnoult C, Demattéi MV, Fouquenet D, Parent C, Heuzé-Vourc'h N, Gouilleux-Gruart V.
Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment.
Front Immunol. 2018 Sep 28;9:2259. doi: 10.3389/fimmu.2018.02259. eCollection 2018.

Cartron G, Letestu R, Dartigeas C, Tout M, Mahé B, Gagez AL, Ferrant E, Guiu B, Villemagne B, Letuan P, Aurrant T, Orsini-Piocelle F, Banos A, Feugier P, Leblond V, de Guibert S, Tournihac O, Dupuis J, Delmer A, Rouillé V, Ternant D, Leprêtre S.
Increased rituximab exposure does not improve response and outcome of CLL patients after FCR. A French Innovative Leukemia Organization (FILO) Study.
Haematologica. 2018 Mar 8. pii: haematol.2017.182352. doi: 10.3324/haematol.2017.182352. [Epub ahead of print]

Croix C, Massip S, Viaud-Massuard MC.
Synthesis of naphthyridin-2(1H)-one derivatives via ring expansion of 3-substituted-1H-pyrrolo[2,3-b]pyridin-2(3H)-one derivatives.
Chem Commun (Camb). 2018 May 29;54(44):5538-5541.

Desvignes C, Passot C, Ternant D, Caulet M, Guérineau C, Lecomte T, Paintaud G.
Development and validation of an ELISA to study panitumumab pharmacokinetics.
Bioanalysis. 2018, 10 : 205-214

Fargier E, Ranchon F, Huot L, Guerre P, Safar V, Dony A, Hequet N, Bachy E, Savouroux S, Fronteau C, Tomaré P, Tournamille JF, Schwiertz V, Vantard N, Le Gouill S, Gyan E, Salles G, Rioufol C.
SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma.
Ann Hematol. 2018, 97 : 123-131

Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, Campana M, Vermes E, Marchand-Adam S.
Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries.
Target Oncol. 2018 Jul 13. doi: 10.1007/s11523-018-0579-9. [Epub ahead of print]

Girerd S, Tosca L, Herault O, Vignon C, Biard D, Aggoune D, Dkhissi F, Bonnet ML, Sorel N, Desterke C, Bennaceur-Griscelli A, Tachdjian G, Guilhot F, Guilhot J, Chomel JC, Turhan AG.
Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells.
Biochem Biophys Res Commun. 2018, 498 : 715-722

Godier A, Garrigue D, Lasne D, Fontana P, Bonhomme F, Collet JP, de Maistre E, Ickx B, Gruel Y, Mazighi M, Nguyen P, Vincentelli A, Albaladejo P, Lecompte T.
Management if antiplatelet therapy for non-elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostatsis (GIHP) and the French study group on thrombosis and haemostasis (GFHT), in collaboration with the French society of anaesthesia and intensive care medicine (SFAR).
Anaesth Crit Care Pain Med. 2018 Oct 23. pii: S2352-5568(18)30415-6.

Godier A, Fontana P, Motte S, Steib A, Bonhomme F, Schlumberger S, Lecompte T, Rosencher N, Susen S, Vincentelli A, Gruel Y, Albaladejo P, Collet JP; French Working Group on perioperative hemostasis (GIHP).
Management Of Antiplatelet Therapy In Patients Undergoing Elective Invasive Procedures Proposals From The French Working Group On Perioperative Hemostasis (Gihp) And The French Study Group On Thrombosis And Hemostasis (Gfht) In Collaboration With The French Society For Anesthesia And Intensive Care (Sfar).
Arch Cardiovasc Dis. 2018, 111 : 210-223

Gruel Y
Analysis of big data for heparin-induced thrombocytopenia: valuable information but also some doubts.
Lancet Haematol. 2018 May;5(5):e188-e189.

Gyan E, Sonet A, Brice P, Anglaret B, Laribi K, Fruchart C, Tilly H, Araujo C, Soubeyran P, Gonzalez H, Morineau N, Nicolas-Virelizier E, Ghesquières H, Salles B, Bouabdallah R, Orfeuvre H, Fahri J, Couturier O, Xerri L, Feugier P; Lymphoma Study Association (LYSA)22.
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15513. [Epub ahead of print]

Hamdan D, Darrouzain F, Bejan-Angoulvant T, Isorni C, Zelek L, Paintaud G, Janin A, Bousquet G.
A novel way to manage trastuzumab cardiotoxicity.
Cancer Chemother Pharmacol. 2018, 81 : 791-796

Hervé-Aubert K, Allard-Vannier E, Joubert N, Lakhrif Z, Alric C, Martin C, Viaud-Massuard MC, Dimier-Poisson I, Aubrey N, Chourpa I.
Impact of Site-Specific Conjugation of ScFv to Multifunctional Nanomedicines Using Second Generation Maleimide.
Bioconjug Chem. 2018 Mar 23. doi: 10.1021/acs.bioconjchem.8b00091. [Epub ahead of print]

Humeau C, Darrouzain F, Gouilleux-Gruart V.
T lymphocyte immunophenotyping in bronchoalveolar lavage on AQUIOS CL® cytometer.
J Immunol Methods. 2018, 461 : 91-99

Ibrahim S, Raoul W, Lecomte T, Paintaud G, Ternant D.
Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab.
Eur J Cancer. 2018, 92:119-120

Le Nail LR, Brennan M, Rosset P, Deschaseaux F, Piloquet P, Pichon O, Le Caignec C, Crenn V, Layrolle P, Hérault O, De Pinieux G, Trichet V
Comparison of Tumor- and Bone Marrow-Derived Mesenchymal Stromal/Stem Cells from Patients with High-Grade Osteosarcoma.
Int J Mol Sci. 2018 Mar 1;19(3). pii: E707.

Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.
Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.
Haemophilia. 2018, 24 : 211-220

Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyetant S, Bieche I, Berger F, de Koning L.
Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
Br J Cancer. 2018 Jun 14. doi: 10.1038/s41416-018-0130-x. [Epub ahead of print]

Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR, Benichou O, Adams DH, Xu W, Nash P.
Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials.
Arthritis Care Res (Hoboken). 2018 Aug 29. doi: 10.1002/acr.23738. [Epub ahead of print]

Mulleman D, Balsa A.
Adalimumab concentration-based tapering strategy: as good as the recommended dosage.
Ann Rheum Dis. 2018 Jan 6. pii: annrheumdis-2017-212376. doi: 10.1136/annrheumdis-2017-212376. [Epub ahead of print]

Narata AP, Amelot A, Bibi R, Herbreteau D, Angoulvant D, Gruel Y, Janot K.
Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms.
Neurosurgery. 2018 Feb 26. doi: 10.1093/neuros/nyy002. [Epub ahead of print]

Oyallon B, Brachet-Botineau M, Logé C, Bonnet P, Souab M, Robert T, Ruchaud S, Bach S, Berthelot P, Gouilleux F, Viaud-Massuard MC, Denevault-Sabourin C.
Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.
Eur J Med Chem. 2018, 154 : 101-109.

Petitcollin A, Leuret O, Tron C, Lemaitre F, Verdier MC, Paintaud G, Bouguen G, Willot S, Bellissant E, Ternant D.
Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot Study.
Inflamm Bowel Dis. 2018, 24 : 1745-1754

Pereira-Gillion C, Marot M, Griffoul-Espitalier I, Andras L, Goupille P, Salliot C.
Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice.
J Rheumatol. 2018 Feb 1. pii: jrheum.170587. doi: 10.3899/jrheum.170587. [Epub ahead of print]

Picou F, Debeissat C, Bourgeais J, Gallay N, Ferrié E, Foucault A, Ravalet N, Maciejewski A, Vallet N, Ducrocq E, Haddaoui L, Domenech J, Hérault O, Gyan E.
n-3 Polyunsaturated Fatty Acids Induce Acute Myeloid Leukemia Cell Death Associated with Mitochondrial Glycolytic Switch and Nrf2 Pathway Activation.
Pharmacol Res. 2018 Aug 21. pii: S1043-6618(18)30351-7. doi: 10.1016/j.phrs.2018.08.015. [Epub ahead of print]

Resseguier N, Rosso-Delsemme N, Beltran Anzola A, Baumstarck K, Milien V, Ardillon L, Bayart S, Berger C, Bertrand MA, Biron-Andreani C, Borel-Derlon A, Castet S, Chamouni P, Claeyssens Donadel S, De Raucourt E, Desprez D, Falaise C, Frotscher B, Gay V, Goudemand J, Gruel Y, Guillet B, Harroche A, Hassoun A, Huguenin Y, Lambert T, Lebreton A, Lienhart A, Martin M, Meunier S, Monpoux F, Mourey G, Negrier C, Nguyen P, Nyombe P, Oudot C, Pan-Petesch B, Polack B, Rafowicz A, Rauch A, Rivaud D, Schneider P, Spiegel A, Stoven C, Tardy B, Trossaërt M, Valentin JB, Vanderbecken S, Volot F, Voyer-Ebrard A, Wibaut B, Leroy T, Sannie T, Chambost H, Auquier P.
Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study.
BMJ Open. 2018 Jul 25;8(7):e022409.

Seren S, Rashed Abouzaid M, Eulenberg-Gustavus C, Hirschfeld J, Nasr Soliman H, Jerke U, N'Guessan K, Dallet-Choisy S, Lesner A, Lauritzen C, Schacher B, Eickholz P, Nagy N, Szell M, Croix C, Viaud-Massuard MC, Al Farraj Aldosari A, Ragunatha S, Ibrahim Mostafa M, Giampieri F, Battino M, Cornillier H, Lorette G, Stephan JL, Goizet C, Pedersen J, Gauthier F, Jenne DE, Marchand-Adam S, Chapple IL, Kettritz R, Korkmaz B.
Consequences of cathepsin C inactivation for membrane exposure of proteinase 3, the target antigen in autoimmune vasculitis.
J Biol Chem. 2018, 293 : 12415-12428.

Ternant D, Azzopardi N, Raoul W, Bejan-Angoulvant T, Paintaud G.
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.
Clin Pharmacokinet. 2018 May 26. doi: 10.1007/s40262-018-0680-3. [Epub ahead of print]

Touzé E, Gruel Y, Gouin-Thibault I, De Maistre E, Susen S, Sie P, Derex L.
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants Expert opinion of the Societe Francaise de Neurologie Vasculaire (SFNV) [French Vascular Neurology Society] and the Groupe Francais d'etudes sur l'Hemostase et la Thrombose (GFHT) [French study Group on Haemostasis and Thrombosis].
Eur J Neurol. 2018 Jan 23. doi: 10.1111/ene.13582. [Epub ahead of print]

Watier H.
Rituximab mechanisms of action in B-CLL: a new piece of the puzzle.
Oncotarget. 2018, 9 : 32732-32733

Wendling D, Lukas C, Prati C, Claudepierre P, Gossec L, Goupille P, Hudry C, Miceli-Richard C, Molto A, Pham T, Saraux A, Dougados M.
2017 Update of French Society for Rheumatology (SFR) Recommendations about the Everyday Management of Patients with Spondyloarthritis.
Joint Bone Spine. 2018 Jan 30. pii: S1297-319X(18)30008-3. doi: 10.1016/j.jbspin.2018.01.006. [Epub ahead of print]